Lunsumio 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0007/G 
This was an application for a group of variations. 
19/10/2023 
SmPC 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
A.6 - Administrative change - Change in ATC 
Code/ATC Vet Code 
IB/0005 
B.II.d.2.d - Change in test procedure for the finished 
10/10/2023 
n/a 
product - Other changes to a test procedure 
(including replacement or addition) 
IA/0006 
B.II.d.2.a - Change in test procedure for the finished 
25/09/2023 
n/a 
product - Minor changes to an approved test 
procedure 
PSUSA/10999
Periodic Safety Update EU Single assessment - 
06/07/2023 
n/a 
PRAC Recommendation - maintenance 
/202212 
mosunetuzumab 
II/0002/G 
This was an application for a group of variations. 
12/05/2023 
n/a 
B.I.e.2 - Introduction of a post approval change 
management protocol related to the AS 
B.II.g.2 - Introduction of a post approval change 
management protocol related to the finished product 
R/0001 
Renewal of the marketing authorisation. 
23/02/2023 
19/04/2023 
Annex II and 
The CHMP, having reviewed the available information on 
PL 
the status of the fulfilment of Specific Obligations and 
having confirmed the positive benefit risk balance, is of the 
opinion that the quality, safety and efficacy of this 
medicinal product continue to be adequately and 
sufficiently demonstrated and therefore recommends the 
renewal of the conditional MA for Lunsumio, subject to the 
Specific Obligations and Conditions as laid down in Annex II 
to the opinion. 
Changes were also made to the PI to bring it in line with 
Page 2/3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the current Agency/QRD template, SmPC guideline and 
other minor editorial changes have been implemented. 
Page 3/3 
 
 
 
 
 
 
